The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지

Clinical Analysis of 312 Patients with Hepatobiliary Cancer in Oriental Hospital

한방병원에 내원한 간담도계 암 환자 312례의 임상 분석

  • Jeong, Tae-Young (Liver-Immune Center, Daejeon Oriental Hospital of Daejeon Univ) ;
  • Park, Bong-Ky (Liver-Immune Center, Daejeon Oriental Hospital of Daejeon Univ) ;
  • Cho, Jung-Hyo (Liver-Immune Center, Daejeon Oriental Hospital of Daejeon Univ) ;
  • Son, Chang-Gue (Liver-Immune Center, Daejeon Oriental Hospital of Daejeon Univ)
  • 정태영 (대전대학교 한의과대학 간장내과학교실) ;
  • 박봉기 (대전대학교 한의과대학 간장내과학교실) ;
  • 조정효 (대전대학교 한의과대학 간장내과학교실) ;
  • 손창규 (대전대학교 한의과대학 간장내과학교실)
  • Published : 2009.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This study sought a clinical analysis of hepatobiliary cancer patients treated by oriental medical therapy. Methods: 312 hepatobiliary cancer patients treated in East-west Cancer Center of Dunsan Oriental Hospital from October 2004 to September 2008 were reviewed. These patients' general characteristics and clinical change after treatment were investigated. Results: 83.3% of patients' tumors were stage IV. The median survival period of stage IV patients was 107.0$\pm$82.2 (IVa), 207.0$\pm$26.8 (IVb) days (hepatocellular carcinoma), 132.0$\pm$15.8 days (cholangiocarcinoma), and 203.0$\pm$24.6 days (gallbladder carcinoma). Conclusions: This study presents the general characteristics of hepatobiliary cancer patients treated by Oriental medical therapies, and thus would be valuable for further studies of Oriental medicine-based cancer treatments.

Keywords

References

  1. National Cancer Information Center, National cancer incidence in 2003-2005 & 5-year survival rate in 1993~2005. 2008. Available at: URL: http://www.cancer.go.kr/cms/statics/incidence/index.html#1. Accessed April 15, 2009.
  2. Lee WC, Park YM. Epidemiology of liver cancer in korean. Jourmal of Korean liver cancer study group. 1999;1:5-12.
  3. Um SH. Recent Trends of HCC in Korea. Jourmal of Korean liver cancer study group. 2005;8:17-26.
  4. Choi MS. Pathogenesis and treatment strategy of primary liver cancer : Selection of treatment in hepatocellular carcinoma. Korean J Hepatol. 2005;11(1):59-70.
  5. Yoon JH. Diagnosis and treatment of cholangiocarcinoma. Korean J Hepatol. 2005;11(1):48-58.
  6. Lee KY, Ahn SI, Choi YM, Lee KY, Cho YU, Sun KC et al. Analysis of prognostic factors after surgery for gallbladder cancer. J Korean Surg Soc. 2005;69(6):476-81.
  7. Choi YM, Kang KC, Ahn SI, Lee KY, Hong KC, Sun KC et al. Clinical analysis of prognostic factors in hepatocellular carcinoma. J Korean Surg Soc. 2003;65(1):42-8.
  8. Bae KB, Kim TH, Choi YK, Paik NW. Surgical treatment and prognosis for 268 patients with billiary tract cancers. J Korean Surg Soc. 2000;58(3):412-9.
  9. Kim HS, Lee JH, Chung JB, Song SY, Kang JK, Park IS et al. Survival factors of gallbladder carcinoma. Kor J Gastroenterol. 2000;35:367-77.
  10. Kim SS, Lee CD, Choi SW, Han NI, Kim JI, Han SW et al. Prognosis and prognostic factors in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Kor J Gastroenterol. 1997;30:72-80.
  11. Lee GK, Lee SK, Yoo YK, Kim DG. Analysis of prognostic factors and clinical features in hilar cholangiocarcinoma. Kor J Gastroenterol. 2007;50(5):286.
  12. Song KS. Non operative local treatment. Korean J Hepatol. 2005;11(2):71-8.
  13. Cho BD, Oh HK, Jang MK, Kyong TY, Lee JM, Kim YB et al. Clinical characteristics and prognosis of the extrahepatic bile duct cancer. Kor J Gastroenterol. 1996;28:251-9.
  14. Chrystal K, Allan S, Forgeson G, Isaacs R. The use of complementary/alternative medicine by cancer patients in a New Zealand regionaol cancer treatment centre. N Z Med J. 2003;116(1168):296.
  15. Gerson-Cwilich R, Serrano-Olvera A, Villalobos-Prieto A. Complementary and alternative medicine (CAM) in Mexican patients with cancer. Clin Transl Oncol. 2006;8(3):200-7. https://doi.org/10.1007/s12094-006-0011-2
  16. Lewith GT, Broomfield J, Prescott P. Complementary cancer care in Southampton: a survey of staff and patients. Complementary Ther Med. 2002;10(2):100-6. https://doi.org/10.1054/ctim.2002.0525
  17. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14(27):4300-8. https://doi.org/10.3748/wjg.14.4300
  18. Lee CI, Shim KY, Kim HY, Choi SY, Bang DG, Cho KS. Clinical Study of the Efficacy of Combined Western-Oriental Medicine for Gastric Cancer and Hepatocellular Carcinoma. The Journal of Korean Oriental Oncology. 2001;7(1):117-29.
  19. Seo SH, Son CK, Cho CK. Clinical Study in 67 Cases of Hepatoma Patients by Oriental Medicine. Korean Journal of Oriental Physiology and Pathology. 2001;15(3):507-12.
  20. Borza MT, Chow E, Bovett G, Davis L, Gillies C. The correlation among patients and health care professionals in assessing functional status using the karnofsky and eastern coorperative oncology group performance status scales. 2004;2(1):59-63. https://doi.org/10.3816/SCT.2004.n.024
  21. Kim WR, Poterucha JJ, Wiesner RH, Larusso NF, Lindor KD, Petz J. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology. 1999;29(6):1644.
  22. Wang JH, Son JY, Shin JW, Son CK. Hepatoprotective effect of CGX via antioxidative properties in acute mice model. Korean J Orient Int Med. 2008;74-81.
  23. Cho JH, Yoo HS, Lee YW, Son CK, Cho CK. Clinical study in 320 cases for cancer patients on the effect Hangamdan. Thesis Collection of Daejeon University, Institute of korean medicine. 2004;12(2):157-75.
  24. Park JW. Practice guideling for diagnosis and treatment of hepatocellular carcinoma. The general rules for the study of primary liver cancer in jourmal of korean liver cancer study group. 2004:57-70.
  25. Park JK, Park CI, Kim NK. Oncology. Seoul:Iljogak. 2007:418-9.
  26. Park KW, Park JW, Kim TH, Choi JI, Kim SH, Park HS et al. Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the national cancer center, korea. Korean J Hepatol. 2007;13:530-42. https://doi.org/10.3350/kjhep.2007.13.4.530
  27. Yoo KE, Jo SH, Heo JS, Choi SH, Kim YI, Moon HJ. Surgical outcome and prognostic factors of primary gallbladder carcinoma. J Korean Surg Soc. 2004;67(5):384-9.
  28. Kim JW, Jo SH, Moon HJ, Heo JS, Choi SH, Joh JW et al. Prognostic factors after major resection for distal extrahepatic cholangiocarcinoma. Kor J Gastroenterol. 2006;46:144-52.
  29. Park SJ, Seo YI, Kim SH, Kim YI, Park HS, Lee SA et al. Prognostic factor analysis of 200 consecutive hepatic resection for hepatocellular carcinoma. Korean J Hepatol. 2005;11:100.
  30. Lee SH, Kim TN, Jang BI, Eun JR, Lee HJ, Lee KH et al. Factors for prognosis of hilar cholangiocarcinoma. Kor J Gastroenterol. 2007;50(5):287
  31. Park JS, Yoon DS, Kim KS, Choi JS, Lee WJ, Chi HS et al. Analysis of prognostic factors after curative resection for gallbladder carcinoma. Kor J Gastroenterol. 2006;48:32-6.
  32. Memon MA, Anwar S, Shiwani MH, Memon B. Gallbladder carcinoma: a retrospective analysis of twenty-two years experience of a single teaching hospital. Int Semin Surg Oncol. 2005;2(1):6. https://doi.org/10.1186/1477-7800-2-6
  33. Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y et al. Gallbladder cancer (GBC):10-year experience at Memorial Sloan-Kettering Cancer Centre(MSKCC). J Surg Oncol. 2008;98(7):485-9. https://doi.org/10.1002/jso.21141
  34. Malik IA. Clinicopathological features and management of gallbladder cancer in Pakistan:a prospective study of 233 cases. J Gastroenterol Hepatol. 2003;18(8):950-3. https://doi.org/10.1046/j.1440-1746.2003.03066.x
  35. Hwakins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11(3):310-5. https://doi.org/10.1245/ASO.2004.03.011
  36. Smith G, Parks R, Madhavan K, Garden O. A 10-year experience in the management of gallbladder cancer. HPB(Oxford). 2003;5(3):159-66.
  37. Farhat MH, Shamseddine AI, Tawil AN, Berjawi G, Sidani C, Shamseddeen W. Prognostic factors in patients with advanced cholangiocarcinoma: role of surgert, chemotherapy and body mass index. World J Gastroenterol. 2008;14(20):3224-30. https://doi.org/10.3748/wjg.14.3224
  38. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol. 2007;37(11):843-51. https://doi.org/10.1093/jjco/hym116
  39. Forsmo HM, Horn A, Viste A, Hoem D, Ovrebo K. Survival and an overview of decision-making in patients with cholangiocarinoma. Hepatobiliary Pancreat Dis Int. 2008;7(4):412-7.